CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
CalDAG-GEFI (CDGI) is a protein highly enriched in the striatum, particularly in the principal spiny projection neurons (SPNs). CDGI is strongly down-regulated in two hyperkinetic conditions related to striatal dysfunction: Huntington's disease and levodopa-induced dyskinesia in Parkinson's disease. We demonstrate that genetic deletion of CDGI in mice disrupts dendritic, but not somatic, M1 muscarinic receptors (M1Rs) signaling in indirect pathway SPNs. Loss of CDGI reduced temporal integration of excitatory postsynaptic potentials at dendritic glutamatergic synapses and impaired the induction of activity-dependent long-term potentiation. CDGI deletion selectively increased psychostimulant-induced repetitive behaviors, disrupted sequence learning, and eliminated M1R blockade of cocaine self-administration. These findings place CDGI as a major, but previously unrecognized, mediator of cholinergic signaling in the striatum. The effects of CDGI deletion on the self-administration of drugs of abuse and its marked alterations in hyperkinetic extrapyramidal disorders highlight CDGI's therapeutic potential.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Neurobiology of disease - 158(2021) vom: 25. Okt., Seite 105473 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crittenden, Jill R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.02.2022 Date Revised 11.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nbd.2021.105473 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329152610 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329152610 | ||
| 003 | DE-627 | ||
| 005 | 20231225204507.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nbd.2021.105473 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329152610 | ||
| 035 | |a (NLM)34371144 | ||
| 035 | |a (PII)S0969-9961(21)00222-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crittenden, Jill R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2022 | ||
| 500 | |a Date Revised 11.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a CalDAG-GEFI (CDGI) is a protein highly enriched in the striatum, particularly in the principal spiny projection neurons (SPNs). CDGI is strongly down-regulated in two hyperkinetic conditions related to striatal dysfunction: Huntington's disease and levodopa-induced dyskinesia in Parkinson's disease. We demonstrate that genetic deletion of CDGI in mice disrupts dendritic, but not somatic, M1 muscarinic receptors (M1Rs) signaling in indirect pathway SPNs. Loss of CDGI reduced temporal integration of excitatory postsynaptic potentials at dendritic glutamatergic synapses and impaired the induction of activity-dependent long-term potentiation. CDGI deletion selectively increased psychostimulant-induced repetitive behaviors, disrupted sequence learning, and eliminated M1R blockade of cocaine self-administration. These findings place CDGI as a major, but previously unrecognized, mediator of cholinergic signaling in the striatum. The effects of CDGI deletion on the self-administration of drugs of abuse and its marked alterations in hyperkinetic extrapyramidal disorders highlight CDGI's therapeutic potential | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Amphetamine | |
| 650 | 4 | |a Cocaine | |
| 650 | 4 | |a Dendritic excitability | |
| 650 | 4 | |a Drug addiction | |
| 650 | 4 | |a Kir2 | |
| 650 | 4 | |a LTP | |
| 650 | 4 | |a M1 muscarinic receptor | |
| 650 | 4 | |a Self-administration | |
| 650 | 4 | |a Stereotypy | |
| 650 | 4 | |a Striatum | |
| 650 | 7 | |a Central Nervous System Stimulants |2 NLM | |
| 650 | 7 | |a Guanine Nucleotide Exchange Factors |2 NLM | |
| 650 | 7 | |a Rasgrp2 protein, mouse |2 NLM | |
| 650 | 7 | |a Receptor, Muscarinic M1 |2 NLM | |
| 700 | 1 | |a Zhai, Shenyu |e verfasserin |4 aut | |
| 700 | 1 | |a Sauvage, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Kitsukawa, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Burguière, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Thomsen, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Martella, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiglieri, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Picconi, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Pescatore, Karen A |e verfasserin |4 aut | |
| 700 | 1 | |a Unterwald, Ellen M |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Walker S |e verfasserin |4 aut | |
| 700 | 1 | |a Housman, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Caine, S Barak |e verfasserin |4 aut | |
| 700 | 1 | |a Sulzer, David |e verfasserin |4 aut | |
| 700 | 1 | |a Calabresi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Anne C |e verfasserin |4 aut | |
| 700 | 1 | |a Surmeier, D James |e verfasserin |4 aut | |
| 700 | 1 | |a Graybiel, Ann M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurobiology of disease |d 1997 |g 158(2021) vom: 25. Okt., Seite 105473 |w (DE-627)NLM089461223 |x 1095-953X |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2021 |g day:25 |g month:10 |g pages:105473 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nbd.2021.105473 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2021 |b 25 |c 10 |h 105473 | ||